New Strategy Doubles Chemo Effectiveness in Treatment-Resistant Cancer

Researchers at Northwestern University have discovered a groundbreaking approach to cancer treatment that doubles the effectiveness of chemotherapy in treatment-resistant cancer. By understanding the intricate organization of genetic material, called chromatin, the team developed a new strategy to prevent cancer cells from adapting and evading treatment. This approach uses an existing FDA-approved drug, celecoxib, to alter chromatin packing and repress plasticity in cancer cells. In a significant breakthrough, the researchers found that combining celecoxib with standard chemotherapy caused a substantial increase in the number of cancer cells that died in lab cultures and animal models of human ovarian cancer.

Key Takeaways:

• The new strategy targets chromatin packing, which is crucial for cancer cell survival, to prevent adaptive abilities in cancer cells.
• The team used a computational model to analyze how chromatin packing influences a cancer cell's odds of survival against chemotherapy and found it could accurately predict cell survival.
• The researchers selected celecoxib, an FDA-approved anti-inflammatory drug, to alter chromatin packing and repress plasticity in cancer cells.
• Combining celecoxib with standard chemotherapy caused a significant increase in the number of cancer cells that died in lab cultures and animal models of human ovarian cancer.
• This approach has the potential to make chemotherapy more effective and reduce the burden of its side effects on patients.
• The study suggests that modulating chromatin conformation might be the key to treating various complex diseases, including heart disease, neurodegenerative diseases, and more.
• The researchers believe that some complex diseases may be rooted in cells' losing their correct transcriptional memories, and reprogramming chromatin conformation could help restore cells' correct memories.

Statistics:

• The new strategy doubled the effectiveness of chemotherapy in treatment-resistant cancer in lab cultures and animal models of human ovarian cancer.
• The team used a combination of imaging, simulations, and systems modeling to analyze how chromatin packing influences cancer cell survival.
• The researchers found that the genome's 3D arrangement acts like a self-learning system, similar to a machine learning algorithm, allowing cells to physically encode memories of gene transcription patterns.
• Chromatin packing is critical for cancer cell survival, and altering this packing architecture can repress plasticity and prevent cancer cells from adapting to treatments.
• Celecoxib, an FDA-approved anti-inflammatory drug, has the potential to become a new class of compounds designed to modulate chromatin conformation.

Sources:

• Northwestern University. "New strategy doubles chemo effectiveness in treatment-resistant cancer." July 23, 2025.
• Backman, V., et al. "Leveraging chromatin packing domains to target chemoevasion in vivo." Proceedings of the National Academy of Sciences, July 22, 2025.
• National Institutes of Health. "U54CA268084, U54CA193419, R01CA228272, R01CA225002, R01CA155284, R01CA165309, T32GM132604, T32GM008152, and T32HL076139."
• National Science Foundation. "EFMA-1830961, EFMA-1830968, EFMA-1830969, CBET-1249311, EFRI-1240416, DGE-0824162, and DGE-184216."
• Lefkovsky Innovation Award.
• Chicago Biomedical Consortium with support from the Searle Funds at The Chicago Community Trust.